What's in Fundación Pública Andaluza Progreso y Salud's pipeline?

Fundación Pública Andaluza Progreso y Salud has 9 drugs in our index: 5 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Fundación Pública Andaluza Progreso y Salud's portfolio?

Top competitors by shared drug class: Charles University, Czech Republic, Dr Madeleine Wilwerth, HaEmek Medical Center, Israel, Ludwig-Maximilians - University of Munich, Post Graduate Institute of Medical Education and Research, Chandigarh.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-p-blica-andaluza-progreso-y-salud.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fundación Pública Andaluza Progreso y Salud — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Pública Andaluza Progreso y Salud pipeline: 5 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Roflumilast alternated days	Roflumilast alternated days	marketed
Subcutaneous glargine insulin	Subcutaneous glargine insulin	marketed
Regular insulin added to TPN bag	Regular insulin added to TPN bag	marketed	Insulin (short-acting)	Insulin receptor	Endocrinology/Metabolic
Hyperbaric bupivacaine+Sufentanil	Hyperbaric bupivacaine+Sufentanil	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)	Anesthesia
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)	Anesthesia / Pain Management
Antipsychotic treatment	Antipsychotic treatment	phase 3	Antipsychotic		Psychiatry/Neurology
Discontinuation antipsychotic treatment	Discontinuation antipsychotic treatment	phase 3			Psychiatry
Amchafibrin	Amchafibrin	phase 3		Plasminogen	Rare Disease

Therapeutic area mix

Anesthesia · 1
Anesthesia / Pain Management · 1
Endocrinology/Metabolic · 1
Other · 1
Psychiatry · 1
Psychiatry/Neurology · 1
Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Charles University, Czech Republic · 1 shared drug class
Dr Madeleine Wilwerth · 1 shared drug class
HaEmek Medical Center, Israel · 1 shared drug class
Ludwig-Maximilians - University of Munich · 1 shared drug class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 shared drug class
Technical University of Munich · 1 shared drug class
The University of Texas Medical Branch, Galveston · 1 shared drug class
University of Genova · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Pública Andaluza Progreso y Salud:

Cite this brief

Drug Landscape (2026). Fundación Pública Andaluza Progreso y Salud — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-p-blica-andaluza-progreso-y-salud. Accessed 2026-05-16.